Stocks of Taysha Gene Therapies Inc (NASDAQ:TSHA) traded higher last session on Wall Street, down -8.99% to $1.26.
TSHA stock price is now -23.06% away from the 50-day moving average and -37.87% away from the 200-day moving average. The market capitalization of the company currently stands at $259.32M.
With the price target of $5, BMO Capital Markets recently initiated with Outperform rating for Taysha Gene Therapies Inc (NASDAQ: TSHA). On April 09, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $9, while ‘Jefferies’ rates the stock as ‘Hold’
In other news, Manning Paul B, 10% Owner bought 1,333,333 shares of the company’s stock on Jun 27 ’24. The stock was bought for $2,999,999 at an average price of $2.25. Upon completion of the transaction, the 10% Owner now directly owns 1,333,333 shares in the company, valued at $1.68 million. A total of 19.51% of the company’s stock is owned by insiders.
During the past 12 months, Taysha Gene Therapies Inc has had a low of $1.17 and a high of $4.32. As of last week, the company has a debt-to-equity ratio of 0.89, a current ratio of 5.41, and a quick ratio of 5.41. The fifty day moving average price for TSHA is $1.6441 and a two-hundred day moving average price translates $2.03615 for the stock.
The latest earnings results from Taysha Gene Therapies Inc (NASDAQ: TSHA) was released for 2024-12-31. The net profit margin was -1071.62% and return on equity was -121.94% for TSHA. The company reported revenue of $2.02 million for the quarter, compared to $3.6 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -43.9 percent.
